<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716546</url>
  </required_header>
  <id_info>
    <org_study_id>CT/09.10</org_study_id>
    <nct_id>NCT01716546</nct_id>
  </id_info>
  <brief_title>Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer</brief_title>
  <official_title>Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination With Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oesophageal Junction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <authority>Greece: National Organization of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose to study the effect of panitumumab when combined with an active
      regimen, such as DCF (Docetaxel/Cisplatin/Fluourouracil), in previously untreated patients
      with advanced cancer of the stomach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators propose a phase I/II study in order to evaluate the effect of panitumumab when
      combined with an active regimen, such as DCF (Docetaxel/Cisplatin/Fluourouracil), in
      chemotherapy - naive patients with advanced cancer of the stomach.

      Investigators hypothesize that the addition of panitumumab to DCF regimen in advanced cancer
      of the stomach and gastroesophageal junction is feasible, well tolerated and could achieve
      an objective response rate of greater than 40%.

      The 2-weekly schedule of DCF will be used as chemotherapy since a recently presented trial
      demonstrated a comparable efficacy but a more favourable toxicity profile comparable to the
      3-weekly schedule.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Every 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be followed for disease evaluation every eight (8) weeks from the first day of chemotherapy until the first documentation of disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be evaluated from the date of the first chemotherapy cycle until the date of first documented progression or date of death from any cause, whichever came first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be evaluated for overall survival from the date of the first chemotherapy cycle until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose of the combination</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be evaluated for toxicity profil on Day 1 of the first two chemotherapy cycle (cycle repeated every 2 weeks)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab plus DCF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Pazopanib: 800mg once a day for up to 2 years from date of first dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven inoperable locally advanced or metastatic adenocarcinoma of the
             stomach (including adenocarcinoma of the gastrooesophageal junction)

          -  Patient's age between 20 and 70 years old

          -  Measurable disease defined by RECIST criteria

          -  Patients with non-measurable disease could be enrolled in the phase I part of the
             study

          -  ECOG performance status ≤ 1

          -  Hgb ≥ 8g/dL, WBC ≥ 3 x 109/L , neutrophils count ≥ 1.5 x 109/L ,  platelets ≥100 x
             109/L, Creatinine clearance ≥50 mL/min, Total bilirubin ≤ 1.5 X UNL, AST, ALT and ALP
             ≤ 2.5 x UNL

          -  No prior chemotherapy or more than 6 months from adjuvant chemotherapy or
             chemo-radiation

          -  Estimated life expectancy more than 3 months

          -  Written informed consent

        Exclusion Criteria:

          -  Gastrointestinal bleeding

          -  Clinically relevant, symptomatic excessive amounts of ascites resulting in patient's
             discomfort

          -  CNS metastases

          -  History of hypersensitivity to fluoropyrimidines, docetaxel or platinum compounds

          -  Any previous chemotherapy or radiotherapy for advanced disease

          -  Patient pregnant or breast feeding, or planning to become pregnant within 6 months
             after the end of treatment

          -  Patient (male or female) is not willing to use highly effective methods of
             contraception (per institutional standard) during treatment and for 6 months (male or
             female) after the end of treatment

          -  Known hypersensitivity reaction to the component of the treatment

          -  Active infection or malnutrition or bowel obstruction

          -  Legal incapacity or limited legal capacity

          -  Definite contraindications for the use of corticosteroids

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan

          -  Chronic inflammation of the bowel

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) ≤ 1 year before enrollment

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the subject to complete the study or sign meaningful informed consent

          -  A second primary tumor other than non-melanoma skin cancer or in situ cervical cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sofia Aggelaki, MD</last_name>
    <phone>+302810392747</phone>
    <email>agelaki@med.uoc.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dora Chatzidaki</last_name>
    <phone>+302810392570</phone>
    <email>dorachat@med.uoc.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Fytrakis, MD</last_name>
      <email>nikos251@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Nikos Kentepozidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikos Fytrakis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalampos Christofyllakis, MD</last_name>
      <email>christofyll@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Charalampos Christofyllakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Giassas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stylianos Giassas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Ag.Georgios&quot; General Hospital of Chania</name>
      <address>
        <city>Chania</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis Koliou, MD</last_name>
      <phone>+306973375489</phone>
      <email>p_koliou@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ioannis Varthalitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Panagiotis Koliou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Maurogianni</last_name>
      <phone>+302810392091</phone>
      <email>marina.st.nurse@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vassilis Georgoulias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Athanasiadis, MD</last_name>
      <phone>+306944521400</phone>
      <email>athanasiadis.athanasios@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Athanasios Athanasiadis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Karadima, MD</last_name>
      <phone>+306975206026</phone>
    </contact>
    <investigator>
      <last_name>Nikolaos Ziras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Karadima, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabalkaniko General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mperedimou</last_name>
      <phone>+302310400489</phone>
    </contact>
    <investigator>
      <last_name>Christos Emmanouilidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Mpoukovinas, MD</last_name>
      <email>ibouk@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Ioannis Mpoukovinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 14, 2013</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced cancer of the stomach</keyword>
  <keyword>Chemotherapy - naive patients</keyword>
  <keyword>DCF</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
